Jeffrey K. Tobias

Jeffrey K. Tobias

Auto-generated profile, based on publicly available information

Jeffrey K. Tobias

Jazz Pharmaceuticals, Palo Alto, CA, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2016 in Pain
Verified
Journal Article
Closed access
RERobert R. Edwards
Robert R. Edwards
RDRobert H. Dworkin
Robert H. Dworkin
DTDennis C. Turk
Dennis C. Turk
MAMartin S. Angst
Martin S. Angst
RDRaymond Dionne
Raymond Dionne
DYDavid Yarnitsky
David Yarnitsky
There is tremendous interpatient variability in the response to analgesic therapy (even for efficacious treatments), which can be the source of great frustration in clinical practice. This has led to calls for “precision medicine” or personalized pain therapeutics (ie, empirically based algorithms that determine the optimal treatments, or treatment combinations, for individual patients) that would presumably improve both the clinical care of patients with pain and the success rates for putative analgesic drugs in phase 2 and 3 clinical trials. However, before implementing this approach, the characteristics of individual patients or subgroups of patients that increase or decrease the response to a specific treatment need to be identified. The challenge is to identify the measurable phenotypic characteristics of patients that are most predictive of individual variation in analgesic treatment outcomes, and the measurement tools that are best suited to evaluate these characteristics. In this article, we present evidence on the most promising of these phenotypic characteristics for use in future research, including psychosocial factors, symptom characteristics, sleep patterns, responses to noxious stimulation, endogenous pain-modulatory processes, and response to pharmacologic challenge. We provide evidence-based recommendations for core phenotyping domains and recommend measures of each domain.

1 December 2008 in The Lancet Neurology
Verified
Journal Article
Closed access
MBMiroslav Backonja
Miroslav Backonja
MWMark S Wallace
Mark S Wallace
EBE Richard Blonsky
E Richard Blonsky
BCBarry J Cutler
Barry J Cutler
PMPhilip Malan
Philip Malan
JTJeffrey Tobias
Jeffrey Tobias

1 May 2010 in Pain
Verified
Journal Article
Closed access
RDRobert H. Dworkin
Robert H. Dworkin
DTDennis C. Turk
Dennis C. Turk
SPSarah Peirce-Sandner
Sarah Peirce-Sandner
RBRalf Baron
Ralf Baron
NBNicholas Bellamy
Nicholas Bellamy
JWJames Witter
James Witter
There has been an increase in the number of chronic pain clinical trials in which the treatments being evaluated did not differ significantly from placebo in the primary efficacy analyses despite previous research suggesting that efficacy could be expected. These findings could reflect a true lack of efficacy or methodological and other aspects of these trials that compromise the demonstration of efficacy. There is substantial variability among chronic pain clinical trials with respect to important research design considerations, and identifying and addressing any methodological weaknesses would enhance the likelihood of demonstrating the analgesic effects of new interventions. An IMMPACT consensus meeting was therefore convened to identify the critical research design considerations for confirmatory chronic pain trials and to make recommendations for their conduct. We present recommendations for the major components of confirmatory chronic pain clinical trials, including participant selection, trial phases and duration, treatment groups and dosing regimens, and types of trials. Increased attention to and research on the methodological aspects of confirmatory chronic pain clinical trials has the potential to enhance their assay sensitivity and ultimately provide more meaningful evaluations of treatments for chronic pain.

10 June 2008 in Neurology
Verified
Journal Article
Closed access
PDF file
DSDavid Simpson
David Simpson
SBStephen Brown
Stephen Brown
JTJeffrey Tobias
Jeffrey Tobias
Background: HIV-associated distal sensory polyneuropathy (HIV-DSP) is a painful condition with limited effective treatment. Capsaicin desensitizes cutaneous nociceptors resulting in reduced pain. We report a placebo-controlled study of a high-concentration capsaicin dermal patch (NGX-4010) for the treatment of painful HIV-DSP.

1 June 2012 in Pain
Verified
Journal Article
Closed access
RDRobert H. Dworkin
Robert H. Dworkin
DTDennis C. Turk
Dennis C. Turk
SPSarah Peirce-Sandner
Sarah Peirce-Sandner
LBLaurie B. Burke
Laurie B. Burke
JFJohn T. Farrar
John T. Farrar
DZDan Ziegler
Dan Ziegler
A number of pharmacologic treatments examined in recent randomized clinical trials (RCTs) have failed to show statistically significant superiority to placebo in conditions in which their efficacy had previously been demonstrated. Assuming the validity of previous evidence of efficacy and the comparability of the patients and outcome measures in these studies, such results may be a consequence of limitations in the ability of these RCTs to demonstrate the benefits of efficacious analgesic treatments vs placebo ("assay sensitivity"). Efforts to improve the assay sensitivity of analgesic trials could reduce the rate of falsely negative trials of efficacious medications and improve the efficiency of analgesic drug development. Therefore, an Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials consensus meeting was convened in which the assay sensitivity of chronic pain trials was reviewed and discussed. On the basis of this meeting and subsequent discussions, the authors recommend consideration of a number of patient, study design, study site, and outcome measurement factors that have the potential to affect the assay sensitivity of RCTs of chronic pain treatments. Increased attention to and research on methodological aspects of clinical trials and their relationships with assay sensitivity have the potential to provide the foundation for an evidence-based approach to the design of analgesic clinical trials and expedite the identification of analgesic treatments with improved efficacy and safety.

1 June 2010 in The Journal of Pain
Verified
Journal Article
Closed access
WKWilliam R. Kennedy
William R. Kennedy
GVGeertrui F. Vanhove
Geertrui F. Vanhove
SLShiao-Ping Lu
Shiao-Ping Lu
JTJeffrey Tobias
Jeffrey Tobias
KBKeith R. Bley
Keith R. Bley
MSMona M. Selim
Mona M. Selim